- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Novartis Launches Tech Prize to Address Unmet MS Community Needs
Novartis-along with WIRED Brand Lab and other collaborators including Techstars, Shift.ms, and the National Multiple Sclerosis Society-has launched the Innovation Prize for Assistive Tech to encourage new technologies that address the unmet needs of the multiple sclerosis community. The Novartis Innovation Prize: Assistive Tech for Multiple Sclerosis (MS) identifies and embraces technology that aims to improve mobility and daily life for people living with MS. Applications are open worldwide to the tech community, innovators, design experts, patient advocates – "anyone with an idea to make everyday life better for those with MS or mobility-limiting disabilities." Applications will be accepted until January 10, 2020 at 17:00 ET and the winners will be announced at the SXSW conference in Austin, Texas on March 13, 2020. In order to develop their innovation, the first-place winner will receive a prize worth $250,000 and the second-place winner will receive $50,000.* *More information can be found at www.wired.com/msinnovationprize
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
